Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson's Disease Models |
Ham, Hyeon Joo
(College of Pharmacy and Medical Research Center, Chungbuk National University)
Yeo, In Jun (College of Pharmacy and Medical Research Center, Chungbuk National University) Jeon, Seong Hee (College of Pharmacy and Medical Research Center, Chungbuk National University) Lim, Jun Hyung (College of Pharmacy and Medical Research Center, Chungbuk National University) Yoo, Sung Sik (College of Pharmacy and Medical Research Center, Chungbuk National University) Son, Dong Ju (College of Pharmacy and Medical Research Center, Chungbuk National University) Jang, Sung-Su (ATGC Co.) Lee, Haksup (ATGC Co.) Shin, Seung-Jin (ATGC Co.) Han, Sang Bae (College of Pharmacy and Medical Research Center, Chungbuk National University) Yun, Jae Suk (College of Pharmacy and Medical Research Center, Chungbuk National University) Hong, Jin Tae (College of Pharmacy and Medical Research Center, Chungbuk National University) |
1 | Wree, A., Mix, E., Hawlitschka, A., Antipova, V., Witt, M., Schmitt, O. and Benecke, R. (2011) Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease. Neurobiol. Dis. 41, 291-298. DOI |
2 | Zhang, Z., Hao, L., Shi, M., Yu, Z., Shao, S., Yuan, Y., Zhang, Z. and Holscher, C. (2021b) Neuroprotective effects of a GLP-2 analogue in the MPTP Parkinson's disease mouse model. J. Parkinsons Dis. 11, 529-543. DOI |
3 | Zhao, Y. F., Tang, Y. and Illes, P. (2021) Astrocytic and oligodendrocytic P2X7 receptors determine neuronal functions in the CNS. Front. Mol. Neurosci. 14, 641570. DOI |
4 | Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I. and Pitossi, F. J. (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131, 1880-1894. DOI |
5 | Choi, D. Y., Lee, M. K. and Hong, J. T. (2013) Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Neurobiol. Dis. 49, 159-168. DOI |
6 | Connolly, B. S. and Lang, A. E. (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670-1683. DOI |
7 | Antipova, V., Hawlitschka, A., Mix, E., Schmitt, O., Drager, D., Benecke, R. and Wree, A. (2013) Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease. J. Neurosci. Res. 91, 838-847. DOI |
8 | Boll, M. C., Alcaraz-Zubeldia, M. and Rios, C. (2011) Medical management of Parkinson's disease: focus on neuroprotection. Curr. Neuropharmacol. 9, 350-359. DOI |
9 | Butler, C. A., Popescu, A., Kitchener, E., Allendorf, D. H., Puigdellivol, M. and Brown, G. C. (2021) Microglial phagocytosis of neurons in neurodegeneration, and its regulation. J. Neurochem. doi: 10.1111/jnc.15327 [Online ahead of print]. DOI |
10 | Chaudhuri, K. R., Healy, D. G. and Schapira, A. H. (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245. DOI |
11 | Coffield, J. A. and Yan, X. (2009) Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J. Pharmacol. Exp. Ther. 330, 352-358. DOI |
12 | Day, M., Wang, Z., Ding, J., An, X., Ingham, C. A., Shering, A. F., Wokosin, D., Ilijic, E., Sun, Z. and Sampson, A. R. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9, 251-259. DOI |
13 | Hawlitschka, A., Antipova, V., Schmitt, O., Witt, M., Benecke, R., Mix, E. and Wree, A. (2013) Intracerebrally applied botulinum neurotoxin in experimental neuroscience. Curr. Pharm. Biotechnol. 14, 124-130. DOI |
14 | Hwang, C. J., Kim, Y. E., Son, D. J., Park, M. H., Choi, D. Y., Park, P. H., Hellstrom, M., Han, S. B., Oh, K. W., Park, E. K. and Hong, J. T. (2017) Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial function. Redox. Biol. 11, 456-468. DOI |
15 | Oldenburg, I. A. and Ding, J. B. (2011) Cholinergic modulation of synaptic integration and dendritic excitability in the striatum. Curr. Opin. Neurobiol. 21, 425-432. DOI |
16 | Jankovic, J. (2004) Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 75, 951-957. DOI |
17 | Liu, M. and Bing, G. (2011) Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis. 2011, 327089. |
18 | Knuepfer, S. and Juenemann, K. P. (2014) Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther. Adv. Urol. 6, 34-42. DOI |
19 | Marsden, C. (1982) The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 32, 514-539. DOI |
20 | Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M. and Nagatsu, T. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150. DOI |
21 | Paxinos, G. and Watson, C. (2006) The Rat Brain in Stereotaxic Coordinates. Hard cover ed. Elsevier. |
22 | Pringsheim, T., Jette, N., Frolkis, A. and Steeves, T. D. (2014) The prevalence of Parkinson's disease: a systematic review and metaanalysis. Mov. Disord. 29, 1583-1590. DOI |
23 | Rossetto, O., Megighian, A., Scorzeto, M. and Montecucco, C. (2013) Botulinum neurotoxins. Toxicon 67, 31-36. DOI |
24 | Sahinkanat, T., Ozkan, K. U., Ciralik, H., Ozturk, S. and Resim, S. (2009) Botulinum toxin-A to improve urethral wound healing: an experimental study in a rat model. Urology 73, 405-409. DOI |
25 | Wang, L., Wang, K., Chu, X., Li, T., Shen, N., Fan, C., Niu, Z., Zhang, X. and Hu, L. (2017) Intra-articular injection of Botulinum toxin A reduces neurogenic inflammation in CFA-induced arthritic rat model. Toxicon 126, 70-78. DOI |
26 | Rojewska, E., Piotrowska, A., Popiolek-Barczyk, K. and Mika, J. (2018) Botulinum toxin type A-a modulator of spinal neuron-glia interactions under neuropathic pain conditions. Toxins 10, 145. DOI |
27 | Ding, J., Guzman, J. N., Tkatch, T., Chen, S., Goldberg, J. A., Ebert, P. J., Levitt, P., Wilson, C. J., Hamm, H. E. and Surmeier, D. J. (2006) RGS4-dependent attenuation of M 4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat. Neurosci. 9, 832-842. DOI |
28 | Bonte, M.-A., El Idrissi, F., Gressier, B., Devos, D. and Belarbi, K. (2021) Protein network exploration prioritizes targets for modulating neuroinflammation in Parkinson's disease. Int. Immunopharmacol. 95, 107526. DOI |
29 | Munoz-Lora, V. R. M., Abdalla, H. B., Cury, A. A. D. B. and Clemente-Napimoga, J. T. (2020) Modulatory effect of botulinum toxin type A on the microglial P2X7/CatS/FKN activated-pathway in antigeninduced arthritis of the temporomandibular joint of rats. Toxicon 187, 116-121. DOI |
30 | Piotrowska, A., Popiolek-Barczyk, K., Pavone, F. and Mika, J. (2017) Comparison of the expression changes after botulinum toxin type A and minocycline administration in lipopolysaccharide-stimulated rat microglial and astroglial cultures. Front. Cell. Infect. Microbiol. 7, 141. DOI |
31 | Stubblefield, M. D., Levine, A., Custodio, C. M. and Fitzpatrick, T. (2008) The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. Arch. Phys. Med. Rehabil. 89, 417-421. DOI |
32 | Zhang, L. Y., Jin, Q. Q., Holscher, C. and Li, L. (2021a) Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regen. Res. 16, 1660-1670. DOI |